BeOne Medicines (SHSE:688235) Cash Flow from Discontinued Operations : ¥0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is BeOne Medicines Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

BeOne Medicines's cash flow from discontinued operations for the three months ended in Mar. 2025 was ¥0 Mil. It means BeOne Medicines received ¥0 Mil from the sale of part of business quarterly. BeOne Medicines's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0 Mil.

BeOne Medicines Cash Flow from Discontinued Operations Historical Data

The historical data trend for BeOne Medicines's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Cash Flow from Discontinued Operations Chart

BeOne Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

BeOne Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

BeOne Medicines Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

BeOne Medicines Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

BeOne Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (SHSE:688235) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany B1ME34:Brazil

Address

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website

https://www.beonemedicines.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines